COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients

June 6, 2021 updated by: Alhasan Mujtaba Al-Mudhaffer

COVID19 and Psychological Health: a Cross Sectional Evaluation of the Risks of Anxiety and Depression Among Patients Diagnosed With Covid 19

The covid-19 pandemic started to spread worldwide since December 2019. It promoted to an exaggerated psychological stress and anxiety in humans due to the intolerable symptoms higher than usual death of many infected patients. This study examines the corona related anxiety and if there is need for drug intervention to treat this anxiety.

To answer these questions, a survey made to the hospitalized patients including sex, age, educational level, Marital state, and a standardized questionnaires (GAD-7 and PHQ-9) which has been validated and shown to possess good psychometric qualities in studies of participants from multiple populations.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Iraq
      • Basra, Iraq, 99999
        • AlFayhaa Teaching hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients with covid19 diagnosed by their healthcare providers

Description

Inclusion Criteria:

- patients with COVID19 willing to participate in the study

Exclusion Criteria:

  • unwilling unable to read or interact with standardized questionnaire unconscious

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
mild covid
moderate covid
severe covid

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
depression
Time Frame: at the time of acute infection, average of 1 month
Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; >20 severe. Minimum 0 maximum 27 points
at the time of acute infection, average of 1 month
anxiety
Time Frame: at the time of acute infection, average of 1 month
Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; >15 severe. Minimum 0, maximum 21 points
at the time of acute infection, average of 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alhasan Mujtaba Al-Mudhaffer

Collaborators

Ministry of Health, Iraq
University of Basrah

Investigators

  • Study Director: Zainab N Abdul-nabi, M.Sc., University of Basrah
  • Study Director: Hiba Dawood, M.Sc., University of Basrah
  • Study Director: Qussay N Almaliki, Ph.D., AlFayhaa Teaching hospital
  • Study Director: Nadheera F Neamah, University of Basrah
  • Principal Investigator: Dania Zydoon, Al-Sader teaching hospital
  • Principal Investigator: Zainab Mahdi, Al-Mawani general hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2020

Primary Completion (Actual)

May 28, 2021

Study Completion (Actual)

June 1, 2021

Study Registration Dates

First Submitted

December 26, 2020

First Submitted That Met QC Criteria

December 29, 2020

First Posted (Actual)

December 30, 2020

Study Record Updates

Last Update Posted (Actual)

June 8, 2021

Last Update Submitted That Met QC Criteria

June 6, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1120 (Other Identifier: Ain Shams University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe